Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, 103 Wenhua Road, Shenhe District, 110016, PR China.
Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, 103 Wenhua Road, Shenhe District, 110016, PR China.
Eur J Med Chem. 2015;96:173-86. doi: 10.1016/j.ejmech.2015.04.018. Epub 2015 Apr 8.
Through a structure-based molecular hybridization approach, a series of novel benzothiazole derivatives bearing indole-based moiety were designed, synthesized and screened for in vitro antitumor activity against four cancer cell lines (HT29, H460, A549 and MDA-MB-231). Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 20a-w with substituted benzyl-1H-indole moiety showed better selectivity against HT29 cancer cell line than other compounds. Compound 20d exhibited excellent antitumor activity with IC50 values of 0.024, 0.29, 0.84 and 0.88 μM against HT29, H460, A549 and MDA-MB-231, respectively. Further mechanism studies indicated that the marked pharmacological activity of compound 20d might be ascribed to activation of procaspase-3 (apoptosis-inducing) and cell cycle arrest, which had emerged as a lead for further structural modifications. Furthermore, 3D-QSAR model (training set: q(2) = 0.850, r(2) = 0.987, test set: r(2) = 0.811) was built to provide a comprehensive guide for further structural modification and optimization.
通过基于结构的分子杂交方法,设计、合成并筛选了一系列新型苯并噻唑衍生物,这些衍生物带有吲哚基部分,用于体外抗肿瘤活性测试,针对四种癌细胞系(HT29、H460、A549 和 MDA-MB-231)进行测试。大多数化合物对所有测试的细胞系都表现出中等至优异的活性。其中,带有取代苄基-1H-吲哚部分的化合物 20a-w 对 HT29 癌细胞系的选择性优于其他化合物。化合物 20d 表现出优异的抗肿瘤活性,其对 HT29、H460、A549 和 MDA-MB-231 的 IC50 值分别为 0.024、0.29、0.84 和 0.88 μM。进一步的机制研究表明,化合物 20d 的显著药理活性可能归因于激活半胱天冬酶-3(诱导凋亡)和细胞周期停滞,这为进一步的结构修饰提供了一个潜在的先导化合物。此外,还建立了三维定量构效关系模型(训练集:q2 = 0.850,r2 = 0.987,测试集:r2 = 0.811),为进一步的结构修饰和优化提供了全面的指导。